Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/16/2025 | $500.00 → $540.00 | Outperform | Mizuho |
| 7/16/2025 | $512.00 → $581.00 | Overweight | Cantor Fitzgerald |
| 7/9/2025 | $600.00 | Perform → Outperform | Oppenheimer |
| 7/2/2025 | $500.00 → $600.00 | Buy | DA Davidson |
| 6/25/2025 | $515.00 → $600.00 | Outperform | Wedbush |
| 6/11/2025 | $540.00 → $605.00 | Buy | Citigroup |
| 5/1/2025 | $430.00 → $494.00 | Overweight | Barclays |
| 5/1/2025 | $475.00 → $500.00 | Buy | Stifel |
8-K - MICROSOFT CORP (0000789019) (Filer)
11-K - MICROSOFT CORP (0000789019) (Filer)
11-K - MICROSOFT CORP (0000789019) (Filer)
4 - MICROSOFT CORP (0000789019) (Issuer)
4 - MICROSOFT CORP (0000789019) (Issuer)
4 - MICROSOFT CORP (0000789019) (Issuer)
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI in healthcare is predicted to not only save lives, but money too. However, the rollout of this industry-changing tech isn't going to happen overnight. The use of AI in healthcare is being pushed by the World Economic Forum (WEF) to provide in its words, a "healthier, more equitable world." A recent study published in Nature introduced a new "AI Affinity Score" designed to measure how comfortable patients are with artificial intelligence in their healthcare journey. The researchers found that factors like education and g
Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market for new therapiesInitiative to support Tevogen Bio's ExacTcell™ pipeline with a goal of enhancing commercial viability and shareholder value WARREN, N.J., July 16, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that following the completion and deployment of the alpha version of PredicTcell™, a proprietary AI-driven target discovery platform, the Company now plans to expand Tevogen.AI to include patient data against identified targets. Supported by Microsoft (NASDAQ:MSFT) and Databricks, Tevogen.AI aims to rapidly analyze electronic health rec
Tevogen.AI's model drastically reduces target analysis and has the potential to generate billions in cost savings across the healthcare system by streamlining early-stage drug discovery, reducing wet lab dependency, and accelerating timelines.Beyond cost savings, Tevogen.AI leadership believes AI-driven drug discovery has the potential to generate billions in top line revenues for companies who are early adopters.With virology datasets curated and alpha model created, Tevogen.AI will now apply PredicTcell to include oncology, expanding its scope and potentially accelerating cancer immunotherapy development. WARREN, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings In
Mizuho reiterated coverage of Microsoft with a rating of Outperform and set a new price target of $540.00 from $500.00 previously
Cantor Fitzgerald reiterated coverage of Microsoft with a rating of Overweight and set a new price target of $581.00 from $512.00 previously
Oppenheimer upgraded Microsoft from Perform to Outperform and set a new price target of $600.00
SC 13G/A - MICROSOFT CORP (0000789019) (Subject)
SC 13G/A - MICROSOFT CORP (0000789019) (Subject)
Borovik, a Harvard Law graduate, brings 20+ years of legal leadership across AI, tech, and defense, including as Director of Legal Affairs at Microsoft and key legal architect behind defense AI leader Helsing's $5Bn scale-up. He brings deep expertise in global negotiations and IP strategy across commercial and defense sectors - working with customers such as NATO, the UN, and Ukrainian forces. Joins as Circus' first core defense executive to accelerate international growth and legal strategy following the CA-M launch as its first autonomous solution for the defense sector and the CA-1 serial production. Circus SE (XETRA: CA1), a global leader in AI software and robotics for the
The Molson Coors Beverage Company ("Molson Coors" or "the company") (NYSE:TAP, TAP.A)) Board of Directors today announced that Christian "Chris" Cocks has been nominated as an independent Class B director for election at the company's Annual Meeting of Stockholders on May 14, 2025. Cocks is a seasoned consumer goods executive who serves as Chief Executive Officer of Hasbro, Inc (NASDAQ:HAS), a leading games, IP and toy company. "With his background evolving a historic business in the consumer goods industry and a track record of driving commercial and operational success, we believe Chris will bring valuable experience and a great voice to our Board. We are very happy to nominate Chris for
Candy Crush All Stars® 2025 kicks off worldwide on March 20, 2025, following last year's tournament where over 15 million players competed for victoryThe massive $1M prize pool is back, and the stakes are just as sweet as ever.From millions of Crushers to just 10 finalists, only the top Crushers will advance to the live Los Angeles final – where they'll battle for the coveted Candy Crush All Stars title.NEW YORK, March 20, 2025 /PRNewswire/ -- BIGGER. BOLDER. SWEETER. King's Candy Crush All Stars is back for its fifth consecutive year, and the tournament is taking the competition to legendary heights. The stakes? A place to compete in the live final and a chance to win a monumental $1M prize
REDMOND, Wash., July 9, 2025 /PRNewswire/ -- Microsoft Corp. will publish fiscal year 2025 fourth-quarter financial results after the close of the market on Wednesday, July 30, 2025, on the Microsoft Investor Relations website at https://www.microsoft.com/en-us/Investor/. A live webcast of the earnings conference call will be made available at 2:30 p.m. Pacific Time. Microsoft (Nasdaq "MSFT" @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI availa
REDMOND, Wash., June 10, 2025 /PRNewswire/ -- Microsoft Corp. on Tuesday announced that its board of directors declared a quarterly dividend of $0.83 per share. The dividend is payable Sept. 11, 2025, to shareholders of record on Aug. 21, 2025. The ex-dividend date will be Aug. 21, 2025. Microsoft (Nasdaq "MSFT" @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI available broadly and doing so responsibly, with a mission to empower every person and
Ending ARR surpasses $4.4 billion, adding $194 million in net new ARR Delivers strong Falcon Flex deal momentum with accounts exceeding $3.2 billion in total deal value, growing more than 6x year-over-year Achieves record cash flow from operations of $384 million and robust free cash flow of $279 million Announces share repurchase authorization of up to $1 billion CrowdStrike Holdings, Inc. (NASDAQ:CRWD), today announced financial results for the first quarter fiscal year 2026, ended April 30, 2025. "We started the fiscal year with record Q1 large deal and MSSP momentum alongside sustained 97% gross retention and consistently strong net retention as the market consolidates on